Pregnancy outcome following first trimester exposure to sumatriptan. 1998

S Shuhaiber, and A Pastuszak, and B Schick, and D Matsui, and G Spivey, and J Brochu, and G Koren
The Motherisk Program, Department of Pediatrics and Research Institute, The Hospital for Sick Children and the University of Toronto, Ontario, Canada.

We prospectively compared pregnancy outcome after exposure to sumatriptan with that of disease-matched controls and nonteratogen controls. There were no differences in the rates of live births, spontaneous abortions, therapeutic abortions, or major birth defects among the three groups. This first prospective report suggests that the use of sumatriptan during organogenesis is not associated with an apparent increased risk of major birth defects.

UI MeSH Term Description Entries
D011247 Pregnancy The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH. Gestation,Pregnancies
D011256 Pregnancy Outcome Results of conception and ensuing pregnancy, including LIVE BIRTH; STILLBIRTH; or SPONTANEOUS ABORTION. The outcome may follow natural or artificial insemination or any of the various ASSISTED REPRODUCTIVE TECHNIQUES, such as EMBRYO TRANSFER or FERTILIZATION IN VITRO. Outcome, Pregnancy,Outcomes, Pregnancy,Pregnancy Outcomes
D011261 Pregnancy Trimester, First The beginning third of a human PREGNANCY, from the first day of the last normal menstrual period (MENSTRUATION) through the completion of 14 weeks (98 days) of gestation. Early Placental Phase,Pregnancy, First Trimester,Trimester, First,Early Placental Phases,First Pregnancy Trimester,First Pregnancy Trimesters,First Trimester,First Trimester Pregnancies,First Trimester Pregnancy,First Trimesters,Phase, Early Placental,Phases, Early Placental,Placental Phase, Early,Placental Phases, Early,Pregnancies, First Trimester,Pregnancy Trimesters, First,Trimesters, First
D011446 Prospective Studies Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group. Prospective Study,Studies, Prospective,Study, Prospective
D005260 Female Females
D005314 Embryonic and Fetal Development Morphological and physiological development of EMBRYOS or FETUSES. Embryo and Fetal Development,Prenatal Programming,Programming, Prenatal
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D012307 Risk Factors An aspect of personal behavior or lifestyle, environmental exposure, inborn or inherited characteristic, which, based on epidemiological evidence, is known to be associated with a health-related condition considered important to prevent. Health Correlates,Risk Factor Scores,Risk Scores,Social Risk Factors,Population at Risk,Populations at Risk,Correlates, Health,Factor, Risk,Factor, Social Risk,Factors, Social Risk,Risk Factor,Risk Factor Score,Risk Factor, Social,Risk Factors, Social,Risk Score,Score, Risk,Score, Risk Factor,Social Risk Factor
D017366 Serotonin Receptor Agonists Endogenous compounds and drugs that bind to and activate SEROTONIN RECEPTORS. Many serotonin receptor agonists are used as ANTIDEPRESSANTS; ANXIOLYTICS; and in the treatment of MIGRAINE DISORDERS. 5-HT Agonists,5-Hydroxytryptamine Agonists,Serotonin Agonists,5-HT Agonist,5-Hydroxytrytamine Agonist,Receptor Agonists, Serotonin,Serotonergic Agonist,Serotonergic Agonists,Serotonin Agonist,Serotonin Receptor Agonist,5 HT Agonist,5 HT Agonists,5 Hydroxytryptamine Agonists,5 Hydroxytrytamine Agonist,Agonist, 5-HT,Agonist, 5-Hydroxytrytamine,Agonist, Serotonergic,Agonist, Serotonin,Agonist, Serotonin Receptor,Agonists, 5-HT,Agonists, 5-Hydroxytryptamine,Agonists, Serotonergic,Agonists, Serotonin,Agonists, Serotonin Receptor,Receptor Agonist, Serotonin

Related Publications

S Shuhaiber, and A Pastuszak, and B Schick, and D Matsui, and G Spivey, and J Brochu, and G Koren
May 1991, American journal of perinatology,
S Shuhaiber, and A Pastuszak, and B Schick, and D Matsui, and G Spivey, and J Brochu, and G Koren
May 1993, JAMA,
S Shuhaiber, and A Pastuszak, and B Schick, and D Matsui, and G Spivey, and J Brochu, and G Koren
March 1997, American journal of perinatology,
S Shuhaiber, and A Pastuszak, and B Schick, and D Matsui, and G Spivey, and J Brochu, and G Koren
March 2021, Multiple sclerosis (Houndmills, Basingstoke, England),
S Shuhaiber, and A Pastuszak, and B Schick, and D Matsui, and G Spivey, and J Brochu, and G Koren
September 1993, American journal of perinatology,
S Shuhaiber, and A Pastuszak, and B Schick, and D Matsui, and G Spivey, and J Brochu, and G Koren
January 1999, American journal of perinatology,
S Shuhaiber, and A Pastuszak, and B Schick, and D Matsui, and G Spivey, and J Brochu, and G Koren
November 2010, Reproductive toxicology (Elmsford, N.Y.),
S Shuhaiber, and A Pastuszak, and B Schick, and D Matsui, and G Spivey, and J Brochu, and G Koren
January 2019, European journal of obstetrics, gynecology, and reproductive biology,
S Shuhaiber, and A Pastuszak, and B Schick, and D Matsui, and G Spivey, and J Brochu, and G Koren
January 1992, Obstetrics and gynecology,
S Shuhaiber, and A Pastuszak, and B Schick, and D Matsui, and G Spivey, and J Brochu, and G Koren
April 1989, Veterinary and human toxicology,
Copied contents to your clipboard!